Verrica Pharmaceuticals
VRCA
48 hedge funds and large institutions have $97M invested in Verrica Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 6 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0% more capital invested
Capital invested by funds: $96.6M → $97M (+$379K)
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.01% less ownership
Funds ownership: 3.42% → 3.41% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Los Angeles Capital Management
Los Angeles,
California
|
+$232K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$231K |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$225K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$202K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$459K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$384K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$352K |
| 4 |
Two Sigma Investments
New York
|
-$194K |
| 5 |
BlackRock
New York
|
-$128K |
VRCA Hedge Fund Activity: Q2 2020 in Review
48 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2020, worth a combined $97M — up 0.39% from $96.6M a quarter earlier.
Fund positioning in VRCA was balanced in Q2 2020: 6 funds opened new positions, 6 closed out, 15 added to existing stakes and 14 trimmed.
The largest buyer was Los Angeles Capital Management, adding an estimated $232K. The largest seller was Squarepoint, exiting entirely with an estimated $459K sold.
- 48 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $97M of Verrica Pharmaceuticals stock for Q2 2020, up 0.39% quarter-over-quarter.
- 6 funds opened new Verrica Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of 0 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2020 was Los Angeles Capital Management, an estimated $232K added.
- The largest Verrica Pharmaceuticals seller in Q2 2020 was Squarepoint, an estimated $459K sold.
Based on aggregated 13F filings for Q2 2020.